Pfizer, BioNTech to Provide 500M COVID Vax Doses to U.S. for Donation

Pfizer Inc. and BioNTech SE plan to provide the U.S. government at a not-for-profit price 500 million doses of the companies’ COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in 1H22. The government will, in turn, donate the Pfizer-BioNTech vaccine doses to low- and lower middle-income countries and organizations that support them.

The U.S. government will allocate the vaccine doses to 92 low- and lower middle-income countries and economies as defined by Gavi’s COVAX Advance Market Commitment (AMC) and the 55 member states of the African Union.

Deliveries of the 200 million doses will begin in August 2021 and continue through the remainder of the year. The 300 million doses for 2022 will be delivered between January and end of June 2022. The U.S. government also has the option for additional doses in 2022. The plan is to produce the doses being purchased by the U.S. government in Pfizer’s U.S. facilities. Those U.S.-based sites involved in the production of the COVID-19 vaccine include Kalamazoo, MI, Andover, MA, Chesterfield, MO, Groton, CT, and McPherson, KS.

To date, Pfizer and BioNTech have shipped 700 million doses to more than 100 countries or territories around the world. Based on current projections, Pfizer and BioNTech expect to manufacture up to 3 billion doses of the COVID-19 vaccine in 2021. The production capacity has consistently grown due to continued enhancements to the vaccine’s supply chain, which include expanding existing facilities, adding more suppliers, and bringing on additional Pfizer/BioNTech sites and contract manufacturers around the world to produce the vaccine. 

The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. FDA, but has been authorized for emergency use.